Why BPaLM regimen not given in child below 14 yr
Reading File
Searching PubMed
BPaLM regimen children pediatric tuberculosis age restriction
Searching the Web
BPaLM regimen not recommended children below 14 years bedaquiline pretomanid age restriction MDR-TB
Finding Sources
Searching PubMed
pretomanid safety pharmacokinetics children pediatric tuberculosis
The WHO sources give a clear, authoritative answer. Here is the complete explanation:
Why BPaLM Is Not Recommended in Children Below 14 Years
The Short Answer: No Pretomanid Data in This Age Group
The WHO's official position (consolidated TB guidelines, 2022/2023 updates) is explicit:
"The lack of safety data on pretomanid in children aged below 14 years was the main barrier for potential extrapolation of the BPaLM/BPaL recommendation to the threshold of being aged below 14 years."
- WHO Consolidated Guidelines on Tuberculosis (NCBI Bookshelf, NBK588557)
Key Clinical Trials Excluded Children
The two pivotal trials that established BPaLM/BPaL both excluded young children:
| Trial | Age Exclusion |
|---|---|
| Nix-TB | Adults only |
| ZeNix | Excluded ages 0-13 years |
| TB-PRACTECAL | Excluded ages 0-14 years |
Because children were not enrolled, no pediatric efficacy or safety analysis could be performed for the full BPaLM combination.
Component-by-Component Breakdown
| Drug | Pediatric Status |
|---|---|
| Bedaquiline (B) | Now approved for ALL ages after WHO 2022 review; used in children with MDR-TB |
| Linezolid (L) | Used in children with MDR-TB; dosing guidance exists |
| Moxifloxacin (M) | Fluoroquinolones used in children with TB (with caution) |
| Pretomanid (Pa) | No safety, PK, or efficacy data in children <14 years - this is the bottleneck |
Pretomanid is the only drug in BPaLM with zero pediatric data. Without knowing the correct dosing, drug exposure, safety profile, or drug interactions in a developing child's body, the regimen cannot be safely offered.
Regulatory Status of Pretomanid
Pretomanid's approval (FDA 2019, EMA) is specifically for adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB. The TB Alliance's own label explicitly states it is for adults - the indication does not extend to children.
What Children Under 14 Get Instead
Children with MDR/RR-TB who are not eligible for BPaLM receive:
- 9-month all-oral regimen (bedaquiline + FQ + linezolid/clofazimine etc.) - preferred for eligible children under 14
- BDLLfxC regimen (Bedaquiline, Delamanid, Linezolid, Levofloxacin, Clofazimine) - a new WHO 2025 option specifically designed for those who cannot receive BPaLM, including children <14 years and pregnant women
- Longer individualized regimens (18 months) using Groups A, B, C drugs per DST profile
In Summary
The age cutoff of 14 years for BPaLM is not arbitrary - it directly corresponds to the youngest age enrolled in TB-PRACTECAL (the main BPaLM trial). Pretomanid has no pharmacokinetic, safety, or dosing data in children under 14, making it impossible to use responsibly in that population. Ongoing pediatric trials (e.g., TB-CHAMP, SHINE) may eventually generate data to extend BPaLM to younger children.
This is a shared conversation. Sign in to Orris to start your own chat.